论文部分内容阅读
目的:比较氯沙坦钾和钙离子拮抗剂(CCB)类药物治疗高血压伴血糖异常的临床效果。方法:研究对象源于本院2014年10月-2015年10月收治的76例高血压伴血糖异常患者,以随机数表法分为对照组和观察组,各38例。对照组采用CCB类药物治疗;观察组采用氯沙坦钾治疗。比较两组患者治疗前后缩压(SP)、舒张压(DP)、空腹血糖(FPG)、餐后血糖(PBG)及糖化血红蛋白(Hb Alc)水平,两组治疗效果和不良反应发生情况。结果:治疗后观察组SP、DP、FPG及PBG水平分别降至(116.67±21.18)mm Hg、(76.38±12.17)mm Hg、(5.93±1.45)mmol/L及(7.16±1.62)mmol/L,与同组治疗前及对照组治疗后比较,差异具有统计学意义(P<0.05);两组治疗总有效率比较,差异具有统计学意义(P<0.05)。治疗期间,两组患者均未出现严重全身不良反应。结论:氯沙坦钾治疗高血压伴血糖异常效果较CCB类药物显著,能有效调节患者血糖、血压水平,安全性良好。
Objective: To compare the clinical efficacy of losartan potassium and calcium channel blocker (CCB) in the treatment of hypertension with abnormal blood glucose. Methods: The subjects from our hospital from October 2014 to October 2015 admitted to 76 cases of abnormal blood glucose patients with random number table divided into control group and observation group, 38 cases in each. The control group was treated with CCB drugs. The observation group was treated with losartan potassium. The systolic blood pressure (SP), diastolic blood pressure (DP), fasting blood glucose (FPG), postprandial blood glucose (PBG) and HbAc were compared between the two groups before and after treatment. The therapeutic effects and adverse reactions were compared between the two groups. Results: The levels of SP, DP, FPG and PBG in the observation group decreased to (116.67 ± 21.18) mm Hg, (76.38 ± 12.17) mm Hg, (5.93 ± 1.45) mmol / L and , Compared with the same group before treatment and after treatment in the control group, the difference was statistically significant (P <0.05); two groups of total effective rate, the difference was statistically significant (P <0.05). During treatment, two groups of patients did not appear serious systemic adverse reactions. Conclusion: Losartan potassium treatment of hypertension with abnormal blood glucose than CCB drugs significantly effective in regulating blood glucose and blood pressure in patients with good safety.